Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INVIGORATE: Reproxalap in seasonal allergic conjunctivitis
NCT04207736Phase 3Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Dec 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic conjunctivitis (SAC) comparing Reproxalap First with Vehicle First (2 arms). Primary endpoint: Subject-Reported Ocular Itching Score. Started Dec 2019; status: completed.
02
Drugs
reproxalap
03
Conditions
seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on NCT04207736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04207736.